Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies ; volume:3 ; number:1-2 ; day:28 ; month:8 ; year:2015 ; pages:47-68 ; date:12.2015
Rare Cancers and Therapy ; 3, Heft 1-2 (28.8.2015), 47-68, 12.2015
- Urheber
-
Larsen, Jeremy T.
Kumar, Shaji
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-015-0009-4
- URN
-
urn:nbn:de:101:1-2411120900278.831693796139
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Larsen, Jeremy T.
- Kumar, Shaji
- SpringerLink (Online service)
Ähnliche Objekte (12)
New therapies in multiple myeloma
Supply chain transformation : evolving with emerging business paradigms
Evolving therapeutic paradigms in ocular graft-versus-host disease
Estrogenic or antiestrogenic therapies for multiple myeloma?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Emerging agents and regimens for multiple myeloma
Chimeric antigen receptor T cell therapies for multiple myeloma
CAR T therapies in multiple myeloma: unleashing the future
Evolving role of high dose stem cell therapy in multiple myeloma
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
New therapies in multiple myeloma
Supply chain transformation : evolving with emerging business paradigms
Evolving therapeutic paradigms in ocular graft-versus-host disease
Estrogenic or antiestrogenic therapies for multiple myeloma?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Emerging agents and regimens for multiple myeloma
Chimeric antigen receptor T cell therapies for multiple myeloma
CAR T therapies in multiple myeloma: unleashing the future
Evolving role of high dose stem cell therapy in multiple myeloma
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
New therapies in multiple myeloma
Supply chain transformation : evolving with emerging business paradigms
Evolving therapeutic paradigms in ocular graft-versus-host disease
Estrogenic or antiestrogenic therapies for multiple myeloma?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Emerging agents and regimens for multiple myeloma
Chimeric antigen receptor T cell therapies for multiple myeloma
CAR T therapies in multiple myeloma: unleashing the future
Evolving role of high dose stem cell therapy in multiple myeloma